WO2023047424A4 - Pharmaceutical acceptable iron (iii) coordination complex having high phosphate binding capacity and preparation thereof - Google Patents
Pharmaceutical acceptable iron (iii) coordination complex having high phosphate binding capacity and preparation thereof Download PDFInfo
- Publication number
- WO2023047424A4 WO2023047424A4 PCT/IN2022/051044 IN2022051044W WO2023047424A4 WO 2023047424 A4 WO2023047424 A4 WO 2023047424A4 IN 2022051044 W IN2022051044 W IN 2022051044W WO 2023047424 A4 WO2023047424 A4 WO 2023047424A4
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- range
- coordination complex
- iii
- iron
- complex
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/26—Iron; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/295—Iron group metal compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
- C07C51/41—Preparation of salts of carboxylic acids
- C07C51/418—Preparation of metal complexes containing carboxylic acid moieties
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to a pharmaceutical acceptable iron (III) coordination complex having high phosphate binding capacity prepared through a cost-effective and an organic solvent free route. The present invention provides a pharmaceutical composition of iron (III) coordination complex which not only releases the desired amount of elemental iron in the desired pH level which is absorbed and assimilated into iron stores but also binds the ferric iron with the higher dietary phosphate which is finally excreted through stool being insolvable. The pharmaceutical composition is industrially acceptable, consumable with less or no side-effects, more effective.
Claims
AMENDED CLAIMS received by the International Bureau on 21 July 2023 (21 .07.2023)
CLAIMS:
1. A pharmaceutically acceptable Iron (III) coordination complex prepared through an organic solvent free route and represented by formula I;
characterized in that, the complex having:
— purity of 90-95% pure
— Phosphate binding capacity in the range of70.26-90 mg-P/g of elemental Iron at pH 7.5 ;
— moisture content in the range of 19.05 to 28 %.
— particle size distribution in the range of Dv (0.1)- 125pm, Dv (0.5)- 726pm and Dv (0.9)- 1940pm.
2. The coordination complex as claimed in claim 1, wherein the purity of Iron (III) coordination complex and water adduct in solution is 70-80%.
3. The coordination complex as claimed in claim 1, wherein the complex is present in the amorphous form.
4. The pharmaceutically acceptable Iron (III) coordination complex as claimed in claim 1, wherein the complex comprises of ferric tricitratedecahydrate.
18
AMENDED SHEET (ARTICLE 19)
5. A process for preparing the pharmaceutically acceptable iron (III) coordination complex through an organic free solvent route comprising the steps of: a. reacting an anhydrous ferric halide with a metal salt of acid in water with stirring at a temperature ranging between 55-85°C for a period of 24-36 hour to obtain a brown precipitate; b. filtering the brown precipitate obtained in step (a) in a nitrogen gas atmosphere at an optimum pressure range to obtain wet cake material; c. drying the wet cake material obtained in step (b) at a temperature in the range of 55 to 85°C for a period of 1 to 8 hours followed by sequential increasing of temperature at 5 degree per 30 to 35 minutes to obtain the pharmaceutically acceptable Iron (III) coordination complex.
6. The process as claimed in claim 5, wherein the ferric halide used is in the range of 50 to 65%. . The process as claimed in claim 6, wherein the halide is a chloride.
8. The process as claimed in claim 5, wherein the metal salt is used in the range of 50 to 65%.
9. The process as claimed in claim 5, wherein the metal salt of acid is citric acid.
10. The process as claimed in claim 9, wherein the metal in metal salt is a sodium based salt.
11. The process as claimed in claim 5, wherein the stirring in step (a) is maintained in the range of 25-40 rpm.
19
AMENDED SHEET (ARTICLE 19)
12. The process as claimed in claim 5, wherein the filtering is performed in step (a) in a nitrogen gas atmosphere at pressure in the range of 600-700 mmHg. 13. The process as claimed in claim 5, wherein the drying is done in drying chamber at a temperature ranging between 50 to 85 °C for a period of 60- 480 minutes.
20
AMENDED SHEET (ARTICLE 19)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN202231025214 | 2022-04-29 | ||
IN202231025214 | 2022-04-29 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2023047424A1 WO2023047424A1 (en) | 2023-03-30 |
WO2023047424A4 true WO2023047424A4 (en) | 2023-09-07 |
Family
ID=85720209
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IN2022/051044 WO2023047424A1 (en) | 2022-04-29 | 2022-11-30 | Pharmaceutical acceptable iron (iii) coordination complex having high phosphate binding capacity and preparation thereof |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2023047424A1 (en) |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3233783A4 (en) * | 2014-12-17 | 2018-06-27 | Biophore India Pharmaceuticals Pvt. Ltd. | Improved method for the synthesis of ferric oraganic compounds |
CN105985232B (en) * | 2015-02-02 | 2018-05-22 | 安徽省新星药物开发有限责任公司 | A kind of high Fe contained ferrum citricum and preparation method thereof |
BR112017018963A2 (en) * | 2015-03-04 | 2018-05-15 | Keryx Biopharmaceuticals Inc | Method to Treat Iron Deficiency Anemia |
-
2022
- 2022-11-30 WO PCT/IN2022/051044 patent/WO2023047424A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
WO2023047424A1 (en) | 2023-03-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FI111078B (en) | Process for the preparation of mometasone furoate monohydrate | |
US9096629B2 (en) | Process of forming iron hydroxypyrone compounds | |
JP2002523514A (en) | Novel hydrate form of alendronate sodium, its production method and its pharmaceutical composition | |
JP2018500308A (en) | Improved method for synthesizing organoiron compounds | |
JP6073929B2 (en) | Germanium complex with amino acid and carboxylic acid, and preparation method thereof | |
US7119217B2 (en) | Tri(alkylcarboxylato)gallium (III) products and pharmaceutical compositions containing them | |
WO2023047424A4 (en) | Pharmaceutical acceptable iron (iii) coordination complex having high phosphate binding capacity and preparation thereof | |
CA2707344C (en) | Stable salts of s-adenosylmethionine and process for the preparation thereof | |
AU2019350699A1 (en) | Process of making calcium alpha-ketoglutarate | |
EP3459933B1 (en) | Solid forms of a pharmaceutically active compound | |
BG64598B1 (en) | Platinum complex, method for its preparation and therapeutic application | |
JPH09507473A (en) | N, N'-bis (2-hydroxybenzyl) ethylenediamine-N, N'-diacetic acid derivative as a chelating agent | |
JP2001515880A (en) | Quaternary ammonium phosphate compound and method for producing the same | |
WO2007096901A1 (en) | Novel dihydrate form of amifostine and process for its preparation | |
CN112321515A (en) | Preparation method of chiral 1-tert-butyl-3-methyl-6-methylpiperazine-1, 3-diformate | |
JP2021080284A (en) | Crystals of monovalent cation salt of 3-hydroxyisovaleric acid, and process for producing the crystals | |
EA017521B1 (en) | Platinum complex compound and utilization of the same | |
US4988789A (en) | Process for preparing glycine hydrochloride | |
JPH06298505A (en) | Calcium hydrogenphosphate, its production and vehicle containing the same substance | |
CN107344950A (en) | A kind of zoledronic acid dihydrate compound | |
WO2014023647A1 (en) | Bortezomib esters and formulations thereof | |
JP2695035B2 (en) | Method for producing 2- (methylthio) barbituric acid | |
CN115819460A (en) | Preparation method of hexachlorocyclotriphosphazene | |
JP2022501351A (en) | Crystal form of 6- (1-acryloylpiperidin-4-yl) -2- (4-phenoxyphenyl) nicotinamide | |
WO2003053985A1 (en) | Pamidronic acid monosodium salt and preparation thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22872367 Country of ref document: EP Kind code of ref document: A1 |